The purpose of this research study is to determine how bictegravir (BIC), also known as GS 9883, and lenacapavir (LEN) affect the HIV-1 infection in your body and compare it with current standard treatment regimens.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Cindy Gay
Medicine-Infectious Diseases
Clinical or Medical
Interventional
HIV/AIDS
24-0150
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
